
Efficacy of Physical Activity and Exercise added to Pharmaceutic Therapy with Denosumab, Romosozumab, Abaloparatide, or Teriparatide in Patients with Osteopenia
The present systematic review determined the effects of physical activity/exercise added to Denosumab, Romosozumab, Abaloparatide or Teriparatide-therapy on bone strength and fall incidence in middle-aged and older people with osteopenia/osteoporosis. A systematic literature search of five electronic databases and two registers (up to 30/05/2023) without language restrictions included studies with (a) postmenopausal women and men ≥45 years, with low bone mass that compared study arms with (b) combined interventions of physical activity/exercise and Denosumab or Romosozumab or Abaloparatide or Teriparatide versus (c) isolated pharmaceutical therapy on (d) Bone Mineral Density (BMD) and prospective fall and/or fracture events (e) applying a randomized controlled study design. Finally only one study that compared the effect of Teriparatide and whole-body vibration versus isolated Teriparatide therapy on bone strength parameters was eligible. This trial reported a significant effect of combined vs. isolated therapy for lumbar spine BMD however not for total hip-, radius- and tibia-BMD, bone microarchitecture or bone turnover biomarkers. Thus, reviewing the literature there is rather limited data on additive effects of exercise on novel pharmaceutic therapy for osteoporosis. Nethertheless, considering age, bone status and physical function of most people under corresponding therapies might already justify the recommendation of exercise programs dedicated to reduce number and impact of falls and fall impact that complement the effects of pharmacological therapy on bone strength. Due to the enormous socioeconomic importance of osteoporosis-induced low trauma fractures more studies should focus on the dissection of the impact of individualized exercise programs when combined with medical treatment.
Sara Kaiser1, Daniel Schoene1, Matthias Kohl2, Simon von Stengel1, Franz Jakob3, Katharina Kerschan-Schindl4, Uwe Lange5, Friederike Thomasius6, Michael Uder1, and Wolfgang Kemmler1,7*